IQ-AI Limited Imaging Biometrics Announces Channel Partnership (9294R)
July 11 2022 - 2:00AM
UK Regulatory
TIDMIQAI
RNS Number : 9294R
IQ-AI Limited
11 July 2022
IQ-AI Limited
("IQ-AI" or the "Company")
Imaging Biometrics Announces Channel Partnership
IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce
that its medical imaging analysis software, IB Clinic(R), is now
available via the newly launched Bayer Calantic platform. This
latest distribution partnership continues IQ-AI's strategy of
making IB Clinic's unique quantitative solutions accessible through
widespread, global networks and marks the culmination of previously
announced integration and validations efforts initiated in
2021.
Artificial intelligence (AI) marketplace platforms provide
clinicians with a one-stop-shop for a wide array of medical imaging
solutions. These platforms simplify and streamline access to proven
tools, allowing clinicians to easily harness the exclusive
capabilities that can benefit patients. IQ-AI intends to accelerate
adoption of IB Clinic for healthcare providers through these global
networks.
"Whilst it is too soon to predict the revenue impact of this new
partnership, we are hopeful that it marks a significant expansion
of availability globally," said Trevor Brown, CEO of IQ-AI.
About IQ-AI Limited
IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Wisconsin-based Imaging Biometrics, LLC (IB), is focused on
delivering quantitative imaging platforms and therapeutics that
transform how clinicians diagnose and treat patients more
efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at
www.imagingbiometrics.com
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Brett Skelly/Vinod Kaushal
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About IQ-AI Limited
IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Wisconsin-based Imaging Biometrics, LLC (IB), is focused on
delivering quantitative imaging platforms and therapeutics that
transform how clinicians diagnose and treat patients more
efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at
www.imagingbiometrics.com
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms
part of retained EU law (as defined in the European Union
(Withdrawal) Act 2018).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTURARRUNUBAUR
(END) Dow Jones Newswires
July 11, 2022 02:00 ET (06:00 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2023 to Apr 2024